AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of Xcell Biosciences.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Xcell Biosciences
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
455 Mission Bay Blvd S San Francisco, CA 94158
Telephone
Telephone
415-937-0321
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The partnership aims to focus on TCR therapy and work through process development, preclinical analysis, and first-in-human trials using Xcellbio’s AVATAR Foundry platform for solid tumors.


Lead Product(s): TCR-based Therapy

Therapeutic Area: Oncology Product Name: TCR-based Therapy

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: AmplifyBio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 20, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration aims to explore novel approaches to improving therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR™ incubator system for cell therapy research and development.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: ElevateBio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 11, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). s. The projects included in the collaboration will use Xcellbio’s AVATAR incubator system to grow.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Labcorp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Proceeds will support the company’s continued growth as a pioneer in built-to-purpose technology platforms for the development and manufacturing of cell and gene-based therapies.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Casdin Capital

Deal Size: $27.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY